Update from Autifony Therapeutics’ QUIET-1 clinical trial

Autifony Therapeutics has now completed a planned interim analysis on the QUIET-1 tinnitus clinical trial with AUT00063. This analysis was conducted to check for evidence of treatment efficacy and to ensure that there were no safety or tolerability signals. Following its review of the results from 58 subjects who have completed the QUIET-1 trial, the Independent Data Monitoring Committee recommended that Autifony terminate recruitment due to lack of efficacy. The Committee compared the outcome of the AUT00063-treated subjects with those that received placebo, and concluded that on a statistical basis it would not be possible to reach the magnitude of positive outcome needed to show improvement over the control.

Read More